Reversal of Misfortune: Practical Insights for Managing Uncontrolled FXa-Inhibitor–Related Bleeding

Monday, October 9

6:00–6:30 am | Registration and Breakfast
6:30–7:30 am | In-person and Virtual Symposium

Location: Grand Ballroom KL | Philadelphia Marriott Downtown

To pre-register or for more information, please click here.

Grantor: AstraZeneca

Speakers

Co-Chair & Presenter:
Truman J. Milling Jr., MD, FACEP
Seton Dell Medical School Stroke Institute
Austin, Texas

Co-Chair & Presenter:
Frank Peacock, MD, FACEP, FACC, FESC
Baylor College of Medicine
Houston, Texas

Symposium Information

Direct-acting oral anticoagulants (DOACs) are the standard of care for many cardiovascular diseases, but like all anticoagulants, their use can be associated with potentially fatal hemorrhage. Specific anticoagulation reversal agents are needed to treat DOAC-associated bleeding. Two agents—idarucizumab and andexanet alfa—have recently been approved to reverse the anticoagulant effects of dabigatran (oral direct thrombin inhibitor) and apixaban and rivaroxaban (oral direct factor Xa inhibitors), respectively. Additional reversal agents are in development. What do clinicians and emergency medicine physicians need to know about using these novel anticoagulation reversal agents?

Come learn in this PeerView Live MasterClass and Practicum! Expert panelists will share what DOAC reversal agents are available, their mechanisms of action, and how they differ from each other and the agents used to reverse other anticoagulants. The experts will share guidance on when and how to select an appropriate factor Xa inhibitor reversal agent and how to incorporate them into emergency care. Tying it all together is a session on team-based approaches to managing life-threatening bleeding in emergency settings. Register now to be part of the solution and reverse the misfortune of factor Xa inhibitor–related bleeding!

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Recognize the urgency of uncontrolled bleeding and the appropriate use of reversal agents for patients receiving DOAC therapy
• Differentiate among available reversal agents according to mechanisms of action and current indications
• Utilize appropriate reversal agents for severe bleeding in patients receiving anticoagulation therapy
• Implement strategies to increase access to DOAC reversal agents in the emergency setting
• Apply an interprofessional, team-based approach to optimize anticoagulation reversal outcomes in the emergency care setting

Support

This activity is supported by an independent educational grant from AstraZeneca LP.

Credit

PVI, PeerView Institute for Medical Education, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.